Through a commercial partnership for ADASUVE (Staccato loxapine), Alexza's lead product, Ferrer is commercializing ADASUVE in Europe, Latin America, Russia, the CIS countries, the Middle East and North Africa countries, Korea, the Philippines and Thailand.
Founded in 1959, Ferrer is a privately-held European R&D-based pharmaceutical company headquartered in Barcelona. It is active in the pharmaceutical, health, fine chemicals and food sectors in Europe, Latin America, Africa, the Middle East, Asia and the United States. In total, Ferrer's human healthcare products are commercialized in more than 95 countries, through 24 international affiliates (including joint ventures) and 70 partners and distributors.
Ferrer carries out activities throughout the full pharmaceutical value chain, from R&D to international marketing, including fine chemical development and the manufacturing of both raw materials and finished pharmaceuticals. Its research centers in Spain and Germany, and manufacturing sites in Europe and Latin America cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and feed sectors. For more information, visit www.ferrer.com.
Through a commercial partnership for ADASUVE (Staccato loxapine), Galen is commercializing ADASUVE in the United States.
Galen is a privately owned, specialty pharmaceutical company, which was established in 1968. From its headquarters in Craigavon, Northern Ireland, Galen commercialises its product portfolio in the US, UK & Ireland through its own sales infrastructure, and collaborates with partners internationally in over 20 countries worldwide. By combining innovation in licensing activities and product development, with a competitive pricing strategy, Galen aims to work closely with healthcare professionals and patients to create long-term value. This approach has been a major factor in the company’s success to date.
Galen is part of the Almac Group, an established, leading contract development and manufacturing organisation providing an extensive range of integrated services to over 600 pharmaceutical and biotech companies globally. Almac now employs in excess of 4,500 highly skilled personnel based throughout Europe, US and Asia, and has a strong reputation for innovation, quality and exceptional customer service. For more information, visit www.galen-pharma.com.
Through an exclusive licensing and supply agreement, Engage Therapeutics will develop and commercialize Staccato® alprazolam. As part of the agreement, Engage Therapeutics holds worldwide development and commercial rights.
Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company’s lead investigational drug is Staccato® alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved alprazolam for the cessation of active and acute epileptic seizures. Staccato alprazolam in a Phase 2a proof of concept study demonstrated reduction of seizure in a photosensitivity model. The product will proceed into an advanced clinical setting leveraging a 505(b)(2) regulatory pathway. Engage Therapeutics is based in Summit, N.J.
For more information, visit www.engagetherapeutics.com.